GlassScriptPhysician profile
Arys Daniel Celaya
NPI 1477506046
$5,180.17
in general payments reported to CMS, 2019-2025
21 companies · $929 in 2025
The $929 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $213 · 2021: $602 · 2022: $969 · 2023: $789 · 2024: $1,201 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,918.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $925.71 | 2019-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $575.42 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $405.85 | 2019-2023 | Velphoro |
| Bard Peripheral Vascular, INC. | $386.01 | 2019-2022 | |
| Nuwellis, INC. | $378.25 | 2021-2024 | Aquadex Smartflow Console |
| Travere Therapeutics, INC. | $260.63 | 2023-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $253.68 | 2022-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $241.37 | 2022-2024 | Terlivaz, Acthar |
| Medtronic, INC. | $232.47 | 2022-2024 | Symplicity G3 |
| Akebia Therapeutics INC | $198.57 | 2019 | |
| Opko Pharmaceuticals, LLC | $173.05 | 2024-2025 | Rayaldee |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $150.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $143.24 | 2024 | |
| Novo Nordisk INC | $125.00 | 2025 | Ozempic |
| Calliditas Therapeutics US INC. | $124.99 | 2025 | Tarpeyo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $124.99 | 2025 | |
| Amgen INC. | $124.31 | 2022 | |
| Ardelyx, INC. | $121.84 | 2024 | Xphozah 30 Mg |
| Ablative Solutions, INC. | $110.81 | 2021 | |
| Janssen Pharmaceuticals, INC | $110.80 | 2022 | |
| Vifor Pharma, INC. | $13.18 | 2023 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arys Celaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.